INTRODUCTION
============

The metabolic syndrome is an emerging global epidemic characterized by the clustering of metabolic abnormalities, such as glucose intolerance and/or type 2 diabetes, dyslipidemia, hypertension, and abdominal obesity, which lead to increased cardiovascular-related mortality ([@b1-cln_67p1209]). Weight gain usually leads to insulin resistance, compensatory hyperinsulinemia, and hypertension through parallel mechanisms that may be connected ([@b2-cln_67p1209]). In normotensive obese subjects, changes in sympathetic nervous system modulation correlate with insulin resistance, and decreased heart rate variability may partly account for the increased cardiovascular risk in these subjects ([@b3-cln_67p1209]).

In the experimental setting, animal models have been used to gain an understanding of obesity-related metabolic disorders, including models of surgical and pharmacological induction of obesity in mice ([@b4-cln_67p1209]) and rats ([@b5-cln_67p1209],[@b6-cln_67p1209]). In mice, the neonatal administration of monosodium glutamate (MSG) causes damage in the hypothalamic and circumventricular areas and results in several neuroendocrine and metabolic abnormalities ([@b7-cln_67p1209]), including hypophagia, obesity, hypoactivity, delayed puberty, and elevated plasma corticosterone levels ([@b8-cln_67p1209]). Furthermore, stunted growth, increased adipose tissue stores, and a marked increase in plasma triglycerides have been noted in rats ([@b9-cln_67p1209]).

Although many of the above characteristics are similar to the characteristics of metabolic syndrome as it occurs in humans, the few studies that have evaluated cardiovascular changes in the MSG-induced obesity animal model have reported conflicting results. Female, but not male, MSG-treated rats exhibit systolic hypotension, and no changes in heart rate were obtained using the indirect tail-cuff method ([@b10-cln_67p1209]). These results suggest that gender may be important in the MSG response. Moreover, reduced vascular responsiveness to alpha-adrenergic stimulation was observed in MSG-treated rats ([@b11-cln_67p1209]). In a similar animal model, ventromedial hypothalamic lesions displayed massive obesity, insulin resistance, low sympathetic activity, high parasympathetic activity, and no changes in blood pressure ([@b6-cln_67p1209]). Although the metabolic aspects of MSG-induced obesity have been extensively examined, it has not been studied in detail concerning cardiovascular autonomic function. Thus, the present study was designed to evaluate cardiovascular autonomic function in rats that received MSG neonatal treatment and the potential relationship between this treatment and metabolic abnormalities.

METHODS
=======

Animals
-------

The experiments were performed using 23 male Wistar rats obtained from the animal facility at the Federal University of Health Sciences of Porto Alegre (Porto Alegre, Brazil). The experimental protocol was approved by the Institutional Animal Care and Use Committee at the Federal University of Health Sciences of Porto Alegre, and this investigation was conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985).

During the first seven days of life, 2 mg/kg of MSG (monosodium glutamate, Sigma, USA) or saline in a similar volume was injected subcutaneously into the rats once per day, as previously described ([@b4-cln_67p1209]). The rats were randomly assigned to either the control (n = 10) or MSG-injected (MSG, n = 13) group. The pups were weaned on the 21st day of life and kept in plastic cages (five per cage) in a temperature-controlled room (22°C) with a 12-hour dark-light cycle (light 07:00-19:00 h). The animals were fed standard laboratory chow and water *ad libitum*, and their body weights were monitored weekly for 33 weeks. The Lee index (b.w.^1/3^ in g/naso-anal length in mm) was measured during the final evaluation.

Hemodynamic assessments
-----------------------

Thirty-three weeks after birth, two catheters filled with 0.06 mL of saline were implanted into the femoral artery of each anesthetized rat (80 mg/kg ketamine and 12 mg/kg xylazine, i.p.). Twenty-four hours later, the arterial cannula was connected to a strain gauge transducer (Blood Pressure XDCR; Kent Scientific, Torrington, CT, USA), and the arterial pressure (AP) signals were recorded over a 30-minute period in conscious animals using a microcomputer equipped with an analog-to-digital converter board (WinDaq, 2 kHz, DATAQ, Springfield, OH, USA). The recorded data were analyzed on a beat-by-beat basis to quantify any changes in the mean AP (MAP) and heart rate (HR). The overall variability of the pulse interval and systolic AP in the time domain was assessed by computing the standard deviation (SD) of the time series ([@b12-cln_67p1209])-([@b14-cln_67p1209]).

Baroreflex sensitivity
----------------------

Sequential bolus injections (0.1 mL) of increasing doses of phenylephrine (0.25 to 32 µg/kg) and sodium nitroprusside (0.05 to 1.6 µg/kg) were given to induce increases or decreases in MAP pressure responses (for each drug), ranging from 5 to 40 mm Hg. Baroreflex sensitivity is expressed as bradycardic (BR) and tachycardic (TR) responses in beats per minute per millimeter of mercury, as described elsewhere ([@b12-cln_67p1209])-([@b14-cln_67p1209]).

Autonomic evaluation
--------------------

The vagal and sympathetic effects were both studied by administering injections of methylatropine (3 mg/kg IV, Sigma) and propranolol (4 mg/kg IV, Sigma) at a maximal volume per injection of 0.2 mL. On the first day of the study, the resting HR was recorded in unrestrained rats that were kept in their own cages. Immediately after the resting HR was recorded, methylatropine was injected. Because the HR response to methylatropine reaches its peak within 10 to 15 minutes, this time interval was standardized before the HR measurement was taken. On the second day of the study, propranolol was administered. The vagal effect (VE) was evaluated as the difference between the maximum HR after the methylatropine injection and the resting HR. The sympathetic effect (SE) was evaluated as the difference between the resting HR and the minimum HR after the propranolol injection ([@b14-cln_67p1209],[@b15-cln_67p1209]).

Metabolic measurements
----------------------

One day after the last cardiovascular evaluation (6-h fasting), blood was collected from the arterial cannula for plasma glucose and insulin evaluation. An oral glucose tolerance test (OGTT, 0.5 g/kg oral) was also performed ([@b16-cln_67p1209]). The blood samples (0.5 mL) were collected through the arterial catheter at baseline and 5, 15, 30 and 60 min after the oral glucose test. Using a glucose oxidase kit (Boehringer Mannheim, Mannheim, Germany), plasma samples were obtained for further glucose analysis. For insulin measurements, a radioimmunoassay was performed using anti-human insulin antibodies (Sigma) and 125I-human insulin as the radiolabel (Amersham). After the evaluations, the animals were sacrificed, and a fat mass (white adipose tissue) and lean mass (gastrocnemius and heart muscle) were weighed from each animal.

Statistical analysis
--------------------

The data are reported as the mean±SEM, and Student\'s unpaired *t-*test was used to compare the values obtained between groups. The insulin response to the glucose overload was evaluated using the area under the curve. Baroreflex sensitivity was evaluated using a regression analysis of different groups, and the slopes were compared using Tukey\'s ANOVA as a post-hoc test. Pearson\'s correlation coefficient was used to identify associations between variables. Differences were considered statistically significant when *p*\<0.05.

RESULTS
=======

The body weight measurements increased in the MSG group (375±6 g) after 33 weeks of follow-up in comparison to the control group (355±5 g) (*p* = 0.03). The Lee index values were also higher in the MSG group as compared to the control group (325±2 *vs*. 315±2 body weight^1/3^ in g/naso-anal length in mm, respectively) (*p* = 0.04), and the MSG group had a greater fat mass (evaluated by the epididymal white adipose tissue) than the control group (1.58±0.02 *vs*. 1.7±0.07 g, respectively) (*p* = 0.01). However, the lean mass was similar between the control and MSG groups, as evaluated by the weights of the gastrocnemius (1.92±0.11 *vs*. 2.02±0.08 g in MSG and control, respectively) (*p* = 0.451) and heart muscles (1.17±0.02 *vs*. 1.17±0.03 g in MSG and control, respectively) (*p* = 1.00).

MSG treatment induced a state of insulin resistance, as demonstrated by the plasma insulin levels during the OGTT ([Figure 1A](#f1-cln_67p1209){ref-type="fig"}). Furthermore, increased levels of fasting plasma glucose (5.13±0.79 mmol/L, *p* = 0.03) and plasma insulin (267±29 pmol/L, *p* = 0.02) were observed in the MSG-treated animals as compared to the control group (3.18±0.24 mmol/l, and 159±22 pmol/L, respectively). As a result, the glucose/insulin index values were significantly lower in the MSG group as compared to the control group (11.9±0.12 *vs*. 32.2±0.08 mmol/pmol x1000, respectively) (*p* = 0.02). The area under the curve for plasma insulin during the OGTT ([Figure 1B](#f1-cln_67p1209){ref-type="fig"}) was higher for MSG-treated rats (22,685±3,184 pmol/L/60 min) as compared to control animals (13,729±2,527 pmol/L/60 min), (*p* = 0.05), confirming a higher level of insulin secretion in these animals in response to the glucose overload.

Regarding the hemodynamic measurements, the MSG-treated group displayed increased systolic, diastolic, and mean arterial pressures as compared to the control group; however, the systolic arterial pressure variability was similar between groups ([Table 1](#t1-cln_67p1209){ref-type="table"}). Although the heart rate was similar between the experimental groups, heart rate variability was reduced in the MSG-treated animals in comparison to the control animals ([Table 1](#t1-cln_67p1209){ref-type="table"}). By plotting the results obtained from all of the control and MSG animals, it was possible to identify a positive correlation between plasma insulin and mean AP (r = 0.69, *p = *0.04), as shown in [Figure 2](#f2-cln_67p1209){ref-type="fig"}. However, there was no relationship between plasma glucose and mean AP (r = 0.19, *p = *0.47).

Baroreflex sensitivity, as evaluated by BR, was reduced in the MSG-treated animals as compared to the control animals, although no differences were observed in the TR between the experimental groups ([Table 1](#t1-cln_67p1209){ref-type="table"}). Furthermore, the vagal and sympathetic effects were reduced in the MSG-treated rats as compared to the control rats, as shown in [Figure 3](#f3-cln_67p1209){ref-type="fig"}.

DISCUSSION
==========

The main finding of the present study was that MSG treatment induced metabolic (increases in body weight, the Lee index, fat mass, hyperinsulinemia, and the insulin response to OGTT) and cardiovascular (increased baseline arterial pressure) changes that were most likely associated with impairments in the autonomic control of circulation and were manifested as reduced heart rate variability, baroreflex sensitivity, and vagal and sympathetic effects. In addition, the high blood pressure values observed were positively correlated with insulin levels.

Insights into the etiology, pathophysiology, and pharmacological treatment of human obesity have arisen from the study of animal models. However, animal obesity models differ widely in the type and extent of obesity. For example, these models are based on environmental factors, (e.g., high-fat diet-induced obesity), spontaneous mutants (i.e., ob/ob and/or db/db mice), genetically engineered animals (e.g., mice with melanocortin receptor subtype-4 gene disruption (knock-out), or mechanical intervention (e.g., chemical or electrical lesions in the ventromedial hypothalamus) and demonstrate different metabolic, hemodynamic, and hormonal results ([@b17-cln_67p1209]).

The neonatal administration of MSG induces obesity in rodents through neuronal damage to the arcuate nucleus-median eminence region ([@b4-cln_67p1209]). This experimental model behaves differently from genetically obese and aurothioglucose-induced (auTG) obese rats ([@b18-cln_67p1209]), as it results in increased lipid mass and mild body weight increases without hyperphagia. In our experiments, increases in body weight, Lee index values, and adipose tissue were observed in MSG-treated rats as compared to control animals, although the lean mass measurements were similar between groups. Consistent with these results, other studies have shown similar changes in these parameters. Ribeiro Braga et al. ([@b19-cln_67p1209]) showed that higher doses of MSG (4 mg/g of body weight) induced increases in carcass fat, cellular size, and weight of the epididymal adipose tissue. In another study ([@b20-cln_67p1209]), MSG treatment (2 mg/g of body weight) during the first four days after birth induced greater retroperitoneal fat mass in comparison to control rats. Moreover, recently published data demonstrated that MSG treatment during the first five postnatal days induced increased fat deposits and hypertension in rats ([@b21-cln_67p1209]).

In the early phase of obesity establishment, normal plasma glucose associated with hyperinsulinemia ([@b22-cln_67p1209]) has been observed, which indicates that insulin resistance is present and that the high insulin levels may be compensatory ([@b2-cln_67p1209],[@b23-cln_67p1209]). Other authors have shown similar results concerning hyperinsulinemia and insulin resistance, suggesting that there is an important decrease in the insulin-stimulated IRS/PI3K/Akt pathway in muscle, which may have an important role in the insulin resistance state ([@b24-cln_67p1209]). In a similar vein, de Souza et al. ([@b25-cln_67p1209]) showed that the hyperinsulinemia observed in MSG-obese rats is, at least in part, a consequence of the direct hypersecretion of ß cells and that chronic aerobic exercise is able to partially counteract the hyperinsulinemic state.

The present study found that MSG treatment during the neonatal period induced a slight increase in arterial pressure (∼8%) in conscious adult rats. In accordance with these data, the study by Cunha et al. ([@b21-cln_67p1209]) demonstrated that the administration of MSG to rats resulted in neuroendocrine obesity and a moderate level of hypertension. Interestingly, in this work, the mean arterial pressure values were positively correlated with the insulin plasma levels, suggesting a cardio-metabolic interaction. Several hypotheses have been postulated to explain the link between hypertension and insulin resistance. Rodents chronically fed high-carbohydrate diets ([@b26-cln_67p1209],[@b27-cln_67p1209]) or chronically infused with exogenous insulin to produce hyperinsulinemia ([@b28-cln_67p1209]) showed increased blood pressure levels, although chronic insulin infusion failed to increase blood pressure measurements in dogs ([@b29-cln_67p1209]). However, acute (1 to 2 h) insulin infusion in rats ([@b30-cln_67p1209]) and dogs ([@b31-cln_67p1209]) has been shown to increase blood pressure, which is most likely the result of sympathetic activation ([@b32-cln_67p1209]) and sodium retention during acute hyperinsulinemia. This rise in blood pressure is not generally sustained because it is overridden by the vasodilator action of insulin, which is rapidly sensed by baroreceptors, and a counterbalancing increase in vasodilation returns the blood pressure to normal. Although these studies may provide insight into the potential role of insulin in hypertension, the quantitative importance of hyperinsulinemia in the etiology of hypertension has not yet been established.

To further explore the mechanisms involved in the cardio-metabolic changes observed in animals treated with MSG, we analyzed the autonomic control of circulation. It is well known that decreased baroreflex sensitivity is a marker of an increased risk of sudden death in patients after myocardial infarction ([@b33-cln_67p1209]), and this measurement has also been associated with increased arterial pressure, myocardial damage, renal lesions, and arterial remodeling ([@b34-cln_67p1209],[@b35-cln_67p1209]). Moreover, there is some evidence correlating the decrease in baroreflex function with body fat distribution, as patients with abdominal obesity demonstrate a greater reduction in baroreflex sensitivity than those with peripheral obesity ([@b35-cln_67p1209]). In fact, children with primarily low baroreflex sensitivity could have a greater predisposition to pathological arterial pressure elevation, and obesity has been shown to be an additive factor to low baroreflex sensitivity in the development of hypertension ([@b36-cln_67p1209]).

In the present study, the reduced bradycardic reflex in MSG-treated rats could have been due to a decrease in the vagal effect on the heart, which may have indicated impairments in the vagal reserve used during heart rate responses evoked by baroreceptors. Indeed, baroreflex-mediated bradycardia is predominantly associated with vagal actions on the heart. If a reduction in this activity occurs, bradycardia is also reduced. Therefore, the attenuation of the bradycardic response may have resulted from reduced responsiveness of the sinus node to parasympathetic modulation, as the vagal effect and (consequently) the HR variability were reduced in MSG-treated rats. In addition, HR variability has been strongly correlated with the vagal indices of HR variability ([@b37-cln_67p1209]). Furthermore, similar results were observed by Miller et al. ([@b38-cln_67p1209]), as rats fed a fructose-rich diet displayed increased arterial pressure levels and reduced baroreflex sensitivity associated with a large reduction in vagal activity. Moreover, we previously observed arterial pressure increases in female fructose-fed rats as well as was a positive correlation between insulin resistance and cardiac vagal effect attenuation ([@b15-cln_67p1209]).

In the present study, we observed a reduced sympathetic effect that was not accompanied by changes in the basal HR or tachycardic responses to AP changes. Moreover, Rehorek et al. ([@b39-cln_67p1209]) suggested that reduced sympathetic activity, as expressed by decreased basal levels of norepinephrine, in MSG-treated rats may be associated with reduced thermogenic responses, which could contribute to the development of obesity. Some evidence has suggested a positive correlation between excess weight gain and sympathetic hyperactivity, which contributes to the development of hypertension in both human and animal models ([@b29-cln_67p1209],[@b40-cln_67p1209]). In fact, Hellstrom ([@b41-cln_67p1209]) presented convincing evidence that the development of a diverse group of diseases, such as hypertension, diabetes and heart disease, is triggered by increased sympathetic neural outflow, which results in endothelial dysfunction, dyslipidemia, inflammation and insulin resistance. Moreover, other data have suggested that autonomic changes modulate hormonal and immune function by inducing the release of bioactive molecules, which are likely involved in the development of cardiometabolic profile changes ([@b42-cln_67p1209],[@b43-cln_67p1209]). In the present work, the reduction in parasympathetic cardiac activity predominated over other sympathetic changes in the MSG group, as only the bradycardic reflex (associated with impaired cardiac vagal effect and variability) was reduced in this group. Together, these results suggest that a relative sympathetic predominance may be associated with the increased arterial pressure observed in MSG-treated rats.

Therefore, our results suggest that the obesity induced by neonatal MSG treatment reduces cardiac autonomic function by most likely contributing to insulin resistance and an increase in arterial pressure.
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###### 

Hemodynamic and autonomic measurements in the control (C) and MSG-treated (MSG) groups.

                    Control    MSG
  ----------------- ---------- ------------
                               
  SAP (mm Hg)       139±2      147±2\*
  DAP (mm Hg)       92±2       99±2\*
  MAP (mm Hg)       112±1      121±2\*
  HR (bpm)          352±11     330±11
  SAP VAR (mm Hg)   6.0±0.3    6.1±0.6
  HR VAR (bpm)      31.8±1.8   4.3±1.6\*
  TR (bpm/mm Hg)    2.5±0.6    2.1±0.5
  BR (bpm/mm Hg)    -1.4±0.3   -0.3±0.5\*

Values are expressed as the mean±SEM. SAP - Systolic arterial pressure; DAP - Diastolic arterial pressure; MAP - Mean arterial pressure; SAP VAR - Systolic arterial pressure variability evaluated according to the standard deviation; HR - Heart rate; HR VAR -- Heart rate variability evaluated according to the standard deviation. \**p\<*0.05 *vs*. control group.
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